DOJ Intervenes in False Claims Suit, Alleges That Regeneron Violated Medicare ASP Reporting Mandates

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

By signing up for a tour of the Thompson FDA Compliance Expert Suite, you are also registering to receive email offers and product updates from us. Simply click unsubscribe at the bottom of any email if you would like to discontinue delivery.

DOJ Intervenes in False Claims Suit, Alleges That Regeneron Violated Medicare ASP Reporting Mandates

Dennis Tosh

April 11, 2024 at 10:55 AM EST

The Department of Justice (DOJ) has filed a complaint in intervention in a qui tam False Claims Act action against a pharmaceutical manufacturer, alleging that it knowingly submitting false Medicare average sales price (ASP) reports to the government (United States ex rel. Nunnelly v. Regeneron Pharmaceuticals, Inc., No. 1:20-cv-11401-PBS (D. Mass.)). Regeneron Pharmaceutical... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

DOJ Intervenes in False Claims Suit, Alleges That Regeneron Violated Medicare ASP Reporting Mandates

My Research Folders

THOMPSON FDA

COMPLIANCE EXPERT

RESOURCES

HELP

CONTACT